DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes.
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
Medical Device Network on MSN
ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...
New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results